This exciting new initiative aims to unblock the pipeline of vital new treatments currently stuck in development stages by supporting specialist CF centres to increase capacity for clinical trials.
While there are over 121 CF drugs in the pipeline, the UK participates in fewer cystic fibrosis clinical trials than its international counterparts. When there aren’t enough people involved in clinical trials, this causes serious delays to the development and approval of vital treatments.
The accelerator platform is going to change all that – co-funded by the Cystic Fibrosis Foundation in America and coordinated by the Trust, this exciting investment will fund new posts in existing CF centres and a new digital hub to allow those interested to find clinical trials relevant to them.
“Faster access to better treatments.”
Ed Owen, Chief Executive of the Trust, said: “Clinical trials are essential to prove the safety and effectiveness of new drugs and ensure they’re available as quickly as possible, but there aren’t enough opportunities for people with CF to be involved in clinical trials at the moment. We’re very proud to launch this accelerator, a key part of our transformational programme to ensure everyone with CF can look forward to a life unlimited by their condition. We’re hoping the Clinical Trials Accelerator Platform will increase the number of clinical trials in the UK, make it easier for people with CF to volunteer to be part of them and make sure that everyone with CF can get faster access to better treatments.”
Preston Campbell, III, MD, president and chief executive officer of the CF Foundation in the US commented: “We are delighted to support the Trust in their work on this very important project, as we know that a world-wide CF community effort is required to effectively conduct CF clinical trials and advance new therapies for people with CF.”
If you are someone living with CF, or a family member or friend of someone with the condition, we want your input! Express your interest in getting involved in our exciting new Clinical Trials Accelerator Platform or apply for our new Patient and Public Involvement Advisor role.